

detect and identify

Characterization of the interaction between recombinant estrogen receptor alpha and transcriptional coactivator SCR-1 NR-2 binding motif through fluorescence polarization study with Mithras LB 940

Arnaud Pillon¹, Jean-Claude Nicolas¹ and Bettina Felletschin²



Figure 1: Principle of the recombinant ERa- fluorescein-NR box 2-binding motif of SRC-1 polarization assay. Agonist-bound recombinant ERa adopts a conformation favouring interaction with the fluorescently labelled LXXLL peptide and the resulting larger complex has a higher polarization value.

Hormonal regulation of gene activity is in part mediated by nuclear receptors (NR) acting as ligand-activated transcription factors (Mangelsdorf al., 1995). These proteins interact with the ligand, the DNA-response element and, in an agonist-dependent manner, with several proteins acting as transcriptional coactivators, such as CBP/p300, and the p160 family proteins (SRC-1, TIF-2, and SRC-3) (Robyr et al., 2000). These protein/protein interactions are mediated by means of two activation functions (AF), AF-1 located in the N-terminal region of the receptor, and AF-2 located in the hormone-binding domain.

¹ INSERM Unité 540, UM I, Endocrinologie Moléculaire et Cellulaire des Cancers 60 rue de Navacelles, 34090 Montpellier, France

² BERTHOLD TECHNOLOGIES, Bad Wildbad, Germany, Bettina.Felletschin@Berthold.com

The crystal structures of the ligand-binding domains of several NR (reviewed by Moras and Gronemeyer, 1998) showed the structural role of helix 12 (H12) in the active/inactive switching of AF-2. In the agonist bound complexes, H12 creates a hydrophobic groove recognized by the coactivator and in contrast, in the antagonist bound complexes, H12 is displaced outward, disrupting this interaction surface. The consensus sequence LXXLL called NR-box is the specific motif of coactivators. It is the dominant factor in modulating their binding to NR, as shown by mutational mapping studies, yeast two-hybrid and GST-pull down interaction experiments (Ding et al., 1998; Feng et al., 1998; Heery et al., 1997; Le Douarin et al., 1996; Mak et al., 1999). SRC-1 contains four NR-boxes. Three of these (NR-boxes 1-3) are located near the core protein, and the fourth one, which is lacking in TIF-2, is found in the C-terminal extremity (Heery et al., 1997; Kalkhoven et al., 1998). Disruption of NR-box 2 has the most profound effect on interaction with estrogen receptor (ER) ligand binding domain (Mak et al., 1999). ER belongs to the NR superfamily and mediates activation of estrogen-responsive genes. In the current model of ER action, ligand binding induces a conformational change in ER leading to a cascade of events including dissociation of bound repressor proteins, recruitment of coactivator proteins possessing histone acetylase activity, local unwinding of chromatin, and subsequent binding of Pol II and other transcriptional factors.

In this study, we quantitatively characterized the interaction of a recombinant ERa produced in bacteria with a fluorescent peptide corresponding to NR box 2-binding motif of the coactivator protein SRC-1 in an *in vitro* high-throughput fluorescence polarization assay using the Mithras LB 940 from BERTHOLD TECHNOLOGIES.

Experimental Procedures

Peptide and ligand

Fluorescent peptide (fluorescein- β A-⁶⁸⁶RHKILHRLLQGS⁶⁹⁸) corresponding to NR box 2binding motif of SRC-1 was purchased from Neosystem (Strasbourg, France) and was kindly provided by Vivian Pogenberg (CNRS U5048 – INSERM U554, Montpellier, France) and described in Pogenberg et al., 2005. 17 β -estradiol (E₂) was purchased from Sigma Chemical Co. (St. Louis, MO, USA) and dissolved in dimethyl sulfoxide at 10⁻² M.

Recombinant receptor production

Recombinant ERa ligand binding domain was produced as already described (Pillon et al., 2005). Briefly, hERa LBD(Lys₃₀₂ \rightarrow Pro₅₅₂) Cys_{(381,417,530}) \rightarrow Ser triple mutant in fusion with six histidine residue plasmid (Gangloff et al., 2001) was produced in BL₂₁ DE₃ electrocompetent *Escherichia coli* cells (Promega, Charbonnières, France). Recombinant ERa was then purified on Ni-NTA-agarose phase (Qiagen, Courtaboeuf, France). The concentration of active recombinant ERa was measured by a [³H]17β-estradiol ligand-binding assay.

Fluorescence polarisation assay

Fluorescence polarization assays were performed using the LB 940 Mithras multimode plate reader from BERTHOLD TECHNOLOGIES (Bad Wildbad, Germany) using a 485 nm excitation filter and a 535 nm emission filter.



Figure 2: LB 940 Mithras Multimode reader from BERTHOLD TECHNOLOGIES.

The buffer solution used for the assays was 100 mM Tris-HCI (pH 8), 10% (vol/vol) glycerol and 1 mg/ml BSA. Estradiol was added to the buffer at sufficient concentration (1 μ M) to saturate receptor and fluorescent peptide concentration which was 50 nM each. For sample preparation dilutions were initiated at the highest protein concentration (0.25 nM) and sample was diluted ten times successively, by a factor of 1.8, in 50 nM fluorescent peptide and 1 μ M estradiol containing buffer, at 4°C to avoid recombinant ERa degradation. Then, 100 μ I of each dilution were transferred in a black 96-well plate

(Fluotrac 200, Greiner Bio-One, Germany), to allow us to establish the titration curve. Fluorescence polarization was measured for 1 second per well when the plate temperature was stabilized at about 20°C within the LB 940 Mithras. Halogen lamp energy for fluorescence excitation was fixed at 65,000.

The G-factor (Gf) used in polarization calculation was first determined as being 0.66 for our fluorescein peptide.

Two emission measurements were needed to evaluate polarization. The first one using a polarized emission filter parallel to the excitation filter (called S-plane) and the second one with a polarized emission filter perpendicular to the excitation filter (called P-plane). Results were expressed in millipolarization (mP) as a function of recombinant ERa amount and mP = $1000 \times (S-bkg)-[Gf \times (P-bkg)] / (S-bkg)+ [Gf \times (P-bkg)]$. Binding affinity of coactivator peptide for recombinant ERa was evaluated by fitting the curve using linear transformation and Scatchard analysis.

Instrument settings

Mithras LB 940 is operated through the Windows[®] PC software MikroWin 2000 from BERTHOLD TECHNOLOGIES which also served as a data evaluation tool. The standard configuration pre-set parameter files for Fluorescence Polarisation readings and G-factor determination are supplied which may be modified according to individual demands. First the G-factor of the selected protein has to be determined.



Figure 3: Selection of G-factor determination parameter file.



Figure 4: Result window: the matrix showing the calculated G-factor.

			1 • ·								
		***	-	***	***	-	***	8.45	-	••	
	2.50	-		200	*255	-	*28	4205	-	-	
	top all Annu formation of the B									+104	
•	***	-12									
	•••	***	-	terres						•••	
		•••			•••		•••			••	
•		••		•••				•••	•	••	•
		12.2	11122	14	2.6	19736	122	24		1	

Figure 5: Selection of the Fluorescence Polarisation parameter file.



Figure 6: Fluorescence Polarisation operation dialogue.

MikroWin - [Result]													_ # ×
P Ele gok yew Bead	Q Read	Print	Export C	Window Help Ala Tempi	ate Calculat	on Results	Ratistics	() Graphics					
E Data		Calculation Status Valid Assay											
- Measurement Data Sample Identifier		1	2	3	4	5	6	7	8	9	10	11	12
Error Information Diution Factor Template Partition	A	299	911	868	940	2771	137	954	792	855	906	838	815
- Groups Overlay Controls Standards	в	163	158	168	135	165	156	156	154	156	137	148	162
E Calculation S plane (raw) P plane (raw) S plane (con)	с	264	267	289	276	296	292	270	281	272	263	234	247
- P plane (con) - mP - Average	D	221	227	199	211	183	163	159	165	760	783	780	780
- S plane (raw) - P plane (raw) - S plane (corr) P plane (corr)	E	137	143	145	144	251	260	265	267	273	270	247	251
Average - Average - Statistics - General Statistics	F	243	246	217	220	198	201	174	172	155	149	121	112
User Statistics 1 User Statistics 2 User Statistics 3 ⊟- Graphics	6	128	134	128	129	250	253	252	250	257	252	238	238
- Bar Utaphics - Curve FR - Kinetics - Scanning - Selection	н	219	226	199	199	174	176	160	160	144	140	136	129
- Control History	15	plane (raw)	2 P plane li	awl 3 5	stane (con)	4 P plane lo	on) 5	mP 6 Ave	nage				
For Help, press F1				m	mmm	Valid Measurem	er.t.	Valid Assay		fp old 110	505.dat *	FP Amaud C	W.par

Figure 7: Result window: Matrix showing the calculated mP values.

Results

In order to obtain large amounts of ERa, we decided to produce a mutant ERa ligand binding domain which would be highly expressed in bacteria. Three of its cysteine residues (381, 417, and 530) were mutated into serine residues, which circumvented aggregation and denaturation problems. The mutant protein bound estradiol with wild type affinity but had limited transcriptional capacity (Gangloff et al., 2001). Furthermore, recombinant ERa was purified on a Ni-NTA-agarose phase in order to clean receptor from bacteria proteins (Pillon et al., 2005) and concentration of active recombinant ERa was measured by a [3 H]17a-estradiol ligand-binding assay that gave a 10 µM purified recombinant ERa solution.

The fluorescent peptide is composed of a fluorescein- β A probe covalently coupled to the N terminus of the NR box 2-binding motif of SRC-1 ⁶⁸⁶RHK1LHRLLQGS⁶⁹⁸. This peptide contains the LXXLL motif required for ER (Pogenberg et al., 2005).

preliminary experiments, we determined the peptide amount sufficient to perform fluorescence polarization assays. Fluorescence detection was thus achieved with successive peptide dilutions to find out the LB 940 Mithras limit of sensibility and efficient fluorescent peptide concentrations (Fig.8).



Figure 8: Fluorescence assay of dilution series of fluorescein-NR box 2-binding motif of SRC-1. Peptide dilution series were prepared and transferred in 96-wells that were introduced into the LB 940 Mithras. The LB 940 Mithras was able to detect 1 nM peptide but the response was perfectly linear from 5 nM on.

The Mithras was able to detect 1 nM fluorescent peptide but a linear response was obtained at about 5 nM. We thus decided to use a ten fold higher concentration and a 50 nM efficient SRC-1 fluorescent peptide concentration was then chosen for fluorescence polarization assays.

The fluorescent peptide interaction with recombinant ERa ligand binding domain was monitored by measuring changes in the steady state fluorescence polarization (Fig.9).



Figure 9: Titration of fluorescein-NR box 2-binding motif of SRC-1 by recombinant ERa in polarization assay. Peptide and dilution series of recombinant ERa in presence of estradiol were prepared and transferred in 96-wells that were introduced into the LB 940 Mithras. Higher polarization values (mP) correspond to greater interaction between recombinant ERa and fluorescent peptide. Each point is a mean of three independent measurements. Fluorescent coactivator peptide binding affinity for recombinant ERa was determined in Figure 10.

The polarization value is the intensity normalized difference between parallel and perpendicular polarized fluorescence emissions and is inversely proportional to the rotational diffusion, thus the larger the molecule, the higher the polarization (Lakowicz, 1991). Dilution series of recombinant ERa in presence of estradiol were achieved in 50 nM peptide containing buffer and the equilibrium was establish rapidly. Each sample (100 μ l) was then transferred in a black 96-well plate and introduced into the Mithras LB 940 for fluorescence polarization detection (Fig.9). Binding affinity of coactivator peptide for recombinant ERa in presence of estradiol was evaluated by fitting the curve using a linear transformation (Fig.10). Scatchard analysis allowed us to determine a K_d value of 7.5 nM. This dissociation constant was in accordance with those found in the literature using fluorescence polarization but with different instruments (Margeat et al., 2001; Ozers et al., 2005).



Figure 10: Fluorescein-NR box 2-binding motif of SRC1 binding ability of recombinant ERa. Binding of SRC-1 peptide to recombinant ERa was performed in presence of estradiol. Fluorescence polarization values represented in Fig.3 were used to determined bound and unbound peptide concentration. Specific bound concentration was calculated after non-specific bound counts were subtracted from total bound counts. (Inset) Linear Scatchard transformation of specific binding gave a K_d of 7.5 nM for recombinant ERa.

Conclusion

We used an approach based on fluorescence polarization to characterize the interaction of the NR box 2-binding motif of SRC-1 coactivator with a recombinant ERa ligand binding domain. In presence of estradiol, the affinity between those two proteins was 7.5 nM. The affinity value we obtained was within the same order of magnitude as previously reported values that were based on other methods (Gee et al., 1999; Zhou et al., 1998, Cheskis et al., 2003). LB 940 Mithras was very convenient to perform fluorescence polarization in multi-well plates with such a stable receptor exhibiting high affinity for coactivators. As the dissociation constant is extremely temperature dependent, experiments were to be performed at as low a temperature as possible. This assay highlighted the usefulness of fluorescent LXXLL-peptide as a tool to probe ligand-dependent recruitment of coactivator to receptors. Working in multi-plates was easier than in tubing system and experiments were performed very fast (less than 2 minutes to read one plate and to get results).

Material list

- -17β-Estradiol (Sigma chemical Co., St. Louis, MO, USA)
- Escherichia coli cell (Promega, Charbonnières, France)
- Ni-NTA Agarose phase (Qiagen, Cortaboeuf, France)
- Mithras LB 940 Multimode Reader (Berthold Technologies, Bad Wildbad, Germany)
- Buffer (100 mM Tris-HCI (ph 8), 10 % (vol/vol) glycerol, 1 mg/ml BSA)
- Microplates 96 well, black (Fluotrac 200, Greiner Bio-One, Germany)

References

- Cheskis BJ, McKenna NJ, Wong CW, Wong J, Komm B, Lyttle CR, O'Malley BW. Hierarchical affinities and a bipartite interaction model for estrogen receptor isoforms and full-length steroid receptor coactivator (SRC/p160) family members. J Biol Chem. 2003 278:13271-7.
- Ding XF, Anderson CM, Ma H, Hong H, Uht RM, Kushner PJ, Stallcup MR. Nuclear receptor-binding sites of coactivators glucocorticoid receptor interacting protein 1 (GRIP1) and steroid receptor coactivator 1 (SRC-1): multiple motifs with different binding specificities. Mol Endocrinol. 1998 12:302-13.
- Feng W, Ribeiro RC, Wagner RL, Nguyen H, Apriletti JW, Fletterick RJ, Baxter JD, Kushner PJ, West BL. Hormonedependent coactivator binding to a hydrophobic cleft on nuclear receptors. Science. 1998 280:1747-9.
- Gangloff M, Ruff M, Eiler S, Duclaud S, Wurtz JM, Moras D. Crystal structure of a mutant hERalpha ligand-binding domain reveals key structural features for the mechanism of partial agonism. J Biol Chem. 2001 276:15059-65. Epub 2001 Feb 06.
- Gee AC, Carlson KE, Martini PG, Katzenellenbogen BS, Katzenellenbogen JA. Coactivator peptides have a differential stabilizing effect on the binding of estrogens and antiestrogens with the estrogen receptor. Mol Endocrinol. 1999 13:1912-23.
- Heery DM, Kalkhoven E, Hoare S, Parker MG. A signature motif in transcriptional co-activators mediates binding to nuclear receptors. Nature. 1997 387:733-6.
- Kalkhoven E, Valentine JE, Heery DM, Parker MG. Isoforms of steroid receptor co-activator 1 differ in their ability to potentiate transcription by the oestrogen receptor. EMBO J. 1998 17:232-43.
- Lakowicz JR. Topics in fluorescence spectroscopy. Plenum Press, New York Vol 2. 1991.
- Le Douarin B, Nielsen AL, Garnier JM, Ichinose H, Jeanmougin F, Losson R, Chambon P. A possible involvement of TIF1 alpha and TIF1 beta in the epigenetic control of transcription by nuclear receptors. EMBO J. 1996 15:6701-15.
- Mak HY, Hoare S, Henttu PM, Parker MG. Molecular determinants of the estrogen receptor-coactivator interface. Mol Cell Biol. 1999 19:3895-903.
- Mangelsdorf DJ, Thummel C, Beato M, Herrlich P, Schutz G, Umesono K, Blumberg B, Kastner P, Mark M, Chambon P. The nuclear receptor superfamily: the second decade. Cell. 1995 83:835-9.
- Margeat E, Poujol N, Boulahtouf A, Chen Y, Muller JD, Gratton E, Cavailles V, Royer CA. The human estrogen receptor alpha dimer binds a single SRC-1 coactivator molecule with an affinity dictated by agonist structure. J Mol Biol. 2001 306:433-42.
- Moras D, Gronemeyer H. The nuclear receptor ligand-binding domain: structure and function. Curr Opin Cell Biol. 1998 10:384-91
- Ozers MS, Ervin KM, Steffen CL, Fronczak JA, Lebakken CS, Carnahan KA, Lowery RG, Burke TJ. Analysis of liganddependent recruitment of coactivator peptides to estrogen receptor using fluorescence polarization. Mol Endocrinol. 2005 19:25-34.
- Pillon A, Boussioux AM, Escande A, Aït-Aïssa S, Gomez E, Fenet H, Ruff M, Moras D, Vignon V, Duchesne MJ, Casellas C, Nicolas JC, Balaguer P. Binding of estrogenic compounds to recombinant estrogen receptor alpha: application to environmental analysis. Env Health Perspec. 2005 113: in press.
- Pogenberg V, Guichou JF, Vivat-Hannah V, Kammerer S, Perez E, Germain P, de Lera AR, Gronemeyer H, Royer CA, Bourguet W. Characterization of the Interaction between Retinoic Acid Receptor/Retinoid X Receptor (RAR/RXR) Heterodimers and Transcriptional Coactivators through Structural and Fluorescence Anisotropy Studies. J Biol Chem. 2005 280:1625-1633.
- Robyr D, Wolffe AP, Wahli W. Nuclear hormone receptor coregulators in action: diversity for shared tasks. Mol Endocrinol. 2000 14:329-47.
- Royer CA, Smith WR, Beechem JM. Analysis of binding in macromolecular complexes: a generalized numerical approach. Anal Biochem. 1990 191:287-94.
- Zhou G, Cummings R, Li Y, Mitra S, Wilkinson HA, Elbrecht A, Hermes JD, Schaeffer JM, Smith RG, Moller DE. Nuclear receptors have distinct affinities for coactivators: characterization by fluorescence resonance energy transfer. Mol Endocrinol. 1998 12:1594-604.